Continuous drug delivery in Parkinson's disease

Area of Science:

• Neurology
• Pharmacology
• Biomedical Engineering

Background:

• Motor and non-motor complications significantly challenge Parkinson's disease (PD) management.
• Fluctuations in drug concentrations cause motor symptom variations (e.g., bradykinesia) and dyskinesias in advanced PD.
• Current treatments often fail to provide consistent therapeutic effects.

Purpose of the Study:

• To review the concept and current status of continuous drug delivery for managing Parkinson's disease.
• To discuss advancements and knowledge gaps in optimizing continuous dopaminergic stimulation.
• To highlight the potential of novel continuous delivery systems for improving patient outcomes.

Main Methods:

• Review of existing literature on continuous drug delivery methods in PD.
• Analysis of pharmacokinetic and pharmacodynamic profiles of various delivery systems.
• Discussion of sustained-release formulations, transdermal patches, and pump-based infusions.

Main Results:

• Continuous infusion therapies (apomorphine, levodopa) reduce motor fluctuations.
• Various strategies like sustained-release formulations and transdermal rotigotine aim for continuous drug concentrations.
• Progress has been made, but optimal use of these alternatives requires further investigation.

Conclusions:

• Continuous drug delivery is a promising strategy for alleviating motor and non-motor complications in Parkinson's disease.
• Ongoing research focuses on developing new treatments for more effective continuous dopaminergic stimulation.
• Future therapies may prevent or delay the progression of late-stage PD complications.